Novartis Ag (NVS)
$89.52 0.07 (0.08%)
18:20 EDT NVS Stock Quote Delayed 15 Minutes
Previous Close $89.52
Market Cap 208.65B
PE Ratio 26.25
Volume (Avg. Vol.) 1.25M
Day's Range 89.39 - 90.12
52-Week Range 72.30 - 96.31
Dividend & Yield 2.98 (3.33%)
NVS Stock Predictions, Articles, and Novartis Ag News
- From InvestorPlace
- From the Web
Ford, Verizon and AbbVie are just a trio of the top dividend stocks to buy for the remainder of 2019, particularly if the broad market hits turbulence.
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.
Of course, the medical opportunity is massive, but Tilray competitor, Canopy Growth (NYSE:CGC), has been aggressively pursuing a multi-pronged approach that inherently diversifies the future revenue streams. CGC’s vision for THC as an ingredient in an array of consumer products separates them from an increasingly crowded industry.
Roku, Autodesk, Splunk and Novartis are our top stock trades on Friday. Going into the long weekend, see why we picked them for next week.
Following a long, steep correction and on the heels of earnings, there’s less to fear in stepping into a contrarian position in Tilray stock.
Forget the volatile marijuana stocks. Their partners could be a better and safer investment for most investors. Here are 3 that stand to benefit from the rise of legal cannabis use.
After a revenue beat Tilray Inc (NASDAQ:TLRY) saw its stock jump 5 percent for the day. However, that optimism has faded rather quickly, and TLRY stock has not been able to capitalize on that momentum.
Altria Group Inc (NYSE:MO) was the latest in a frenzied string of M&A and partnerships in the cannabis sector. Marijuana stocks have been the target of billion-dollar investments, and the $102 billion market cap company and owner of veteran cigarette brands Marlboro, Parliament, and Virginia Slims, last month that it was investing approximately $1.8 billion in Canadian-based Cronos Group Inc (NASDAQ:CRON), which is listed both on the TSX as well as the NASDAQ.
The stock charts of INCY, LYB and FMC are going to start this week's hump-day at a precipice. Here are the numbers to know.
Novartis news about the company's spin-off of Alcon into its own publicly-traded company has NVS stock falling hard on Tuesday.
Tilray stock is still very expensive, even after its partnership with Novartis' Sandoz. However, TLRY is in a very tradable range.
Novartis (NVS) stock got a boost today after the company announced plans to spin off its Alcon business sometime next year.
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
Novartis (NVS) stock took a hit on Thursday following the release of its earnings report for the first quarter of the year.
Novartis put its excess cash to good use by broadening its business into the gene therapy market. Competition could prove tough for NVS stock, but Novartis is ready for the challenge ahead.
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!